New combo therapy aims to save rectums from surgery
NCT ID NCT06417476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving either short-course radiation or long-course chemoradiation, followed by a strong chemotherapy cocktail (mFOLFOXIRI), can shrink low rectal tumors enough to avoid radical surgery. About 66 adults with stage T2-4a rectal cancer whose tumor is within 8 cm of the anus will be randomly assigned to one of the two radiation approaches. The main goal is to see how many patients can keep their rectum for at least one year without needing major surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
651 Dongfeng Road East
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Could cutting one amino acid make rectal cancer treatment more effective?
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery